CN109071544A - 三并环类化合物及其应用 - Google Patents

三并环类化合物及其应用 Download PDF

Info

Publication number
CN109071544A
CN109071544A CN201880001646.8A CN201880001646A CN109071544A CN 109071544 A CN109071544 A CN 109071544A CN 201880001646 A CN201880001646 A CN 201880001646A CN 109071544 A CN109071544 A CN 109071544A
Authority
CN
China
Prior art keywords
compound
synthesis
added
alkyl
400mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880001646.8A
Other languages
English (en)
Other versions
CN109071544B (zh
Inventor
贺海鹰
王静
江志赶
杨亚讯
邵鹏
张臣
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujian Guangsheng Zhonglin Biotechnology Co ltd
Original Assignee
Medshine Discovery Inc
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc, Fujian Cosunter Pharmaceutical Co Ltd filed Critical Medshine Discovery Inc
Publication of CN109071544A publication Critical patent/CN109071544A/zh
Application granted granted Critical
Publication of CN109071544B publication Critical patent/CN109071544B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明公开了式(Ⅰ)所示化合物、其互变异构体或其药学上可接受的盐,并公开了其在制备治疗HBV相关疾病药物中的应用。

Description

PCT国内申请,说明书已公开。

Claims (18)

  1. PCT国内申请,权利要求书已公开。
CN201880001646.8A 2017-02-23 2018-02-09 三并环类化合物及其应用 Active CN109071544B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2017101003091 2017-02-23
CN201710100309 2017-02-23
CN201710648155 2017-08-01
CN201710648155X 2017-08-01
CN201810008592 2018-01-04
CN201810008592X 2018-01-04
PCT/CN2018/075995 WO2018153285A1 (zh) 2017-02-23 2018-02-09 三并环类化合物及其应用

Publications (2)

Publication Number Publication Date
CN109071544A true CN109071544A (zh) 2018-12-21
CN109071544B CN109071544B (zh) 2020-03-17

Family

ID=63253508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880001646.8A Active CN109071544B (zh) 2017-02-23 2018-02-09 三并环类化合物及其应用

Country Status (23)

Country Link
US (1) US11053260B2 (zh)
EP (1) EP3587420B1 (zh)
JP (1) JP6764039B2 (zh)
KR (1) KR102085497B1 (zh)
CN (1) CN109071544B (zh)
AU (1) AU2018223435B2 (zh)
BR (1) BR112019017603A2 (zh)
CA (1) CA3054324C (zh)
DK (1) DK3587420T3 (zh)
ES (1) ES2874656T3 (zh)
HU (1) HUE054822T2 (zh)
IL (1) IL268827A (zh)
LT (1) LT3587420T (zh)
MX (1) MX2019010042A (zh)
MY (1) MY175445A (zh)
PH (1) PH12019501955A1 (zh)
PL (1) PL3587420T3 (zh)
PT (1) PT3587420T (zh)
RS (1) RS61913B1 (zh)
SG (1) SG11201907725SA (zh)
SI (1) SI3587420T1 (zh)
WO (1) WO2018153285A1 (zh)
ZA (1) ZA201906135B (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110872307A (zh) * 2019-06-05 2020-03-10 河南科技大学第一附属医院 一种医院妇科所用噻唑类药物分子及其制备方法和应用
CN112334137A (zh) * 2018-05-03 2021-02-05 埃默里大学 用于nash和其他代谢紊乱的孤儿核受体调节剂
TWI746110B (zh) * 2019-08-15 2021-11-11 大陸商福建廣生堂藥業股份有限公司 氧氮雜卓類化合物的製備方法
CN114456099A (zh) * 2022-02-21 2022-05-10 八叶草健康产业研究院(厦门)有限公司 一种4-氯吡咯-2-羧酸的制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7118354B2 (ja) 2018-08-23 2022-08-16 福建▲広▼生中霖生物科技有限公司 三環式化合物の結晶形及びその使用
WO2021213445A1 (zh) * 2020-04-22 2021-10-28 南京明德新药研发有限公司 内磺酰胺衍生物及其应用
CN115515596A (zh) * 2020-05-15 2022-12-23 福建广生中霖生物科技有限公司 包含三并环类化合物的组合及其在制备治疗hbv药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106413402A (zh) * 2014-03-13 2017-02-15 美国印第安纳大学研究和技术公司 乙型肝炎核心蛋白变构调节剂
CN106459032A (zh) * 2014-05-13 2017-02-22 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类
WO2017069279A1 (ja) * 2015-10-23 2017-04-27 武田薬品工業株式会社 複素環化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2443703C2 (ru) 2007-06-18 2012-02-27 Саншайн Лейк Фарма Ко., Лтд Бром-фенил замещенные тиазолилдигидропиримидины
CN102060786A (zh) 2011-01-20 2011-05-18 天津大学 4-(取代-1,3-二炔基)-4-(三氟甲基)-3,4-二氢取代喹唑啉-2-酮类化合物及其制备方法和应用
ES2640063T3 (es) 2013-04-03 2017-10-31 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
ES2777248T3 (es) 2013-11-14 2020-08-04 Novira Therapeutics Inc Derivados de azepano y métodos de tratar infecciones por hepatitis B
TWI721016B (zh) * 2015-09-15 2021-03-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
EP3512845A1 (en) 2016-09-15 2019-07-24 Assembly Biosciences, Inc. Hepatitis b core protein modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106413402A (zh) * 2014-03-13 2017-02-15 美国印第安纳大学研究和技术公司 乙型肝炎核心蛋白变构调节剂
CN106459032A (zh) * 2014-05-13 2017-02-22 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类
WO2017069279A1 (ja) * 2015-10-23 2017-04-27 武田薬品工業株式会社 複素環化合物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112334137A (zh) * 2018-05-03 2021-02-05 埃默里大学 用于nash和其他代谢紊乱的孤儿核受体调节剂
CN110872307A (zh) * 2019-06-05 2020-03-10 河南科技大学第一附属医院 一种医院妇科所用噻唑类药物分子及其制备方法和应用
TWI746110B (zh) * 2019-08-15 2021-11-11 大陸商福建廣生堂藥業股份有限公司 氧氮雜卓類化合物的製備方法
CN114456099A (zh) * 2022-02-21 2022-05-10 八叶草健康产业研究院(厦门)有限公司 一种4-氯吡咯-2-羧酸的制备方法

Also Published As

Publication number Publication date
CN109071544B (zh) 2020-03-17
CA3054324A1 (en) 2018-08-30
LT3587420T (lt) 2021-07-12
EP3587420A1 (en) 2020-01-01
SG11201907725SA (en) 2019-09-27
RS61913B1 (sr) 2021-06-30
JP2020508342A (ja) 2020-03-19
KR102085497B1 (ko) 2020-03-05
PT3587420T (pt) 2021-06-04
HUE054822T2 (hu) 2021-10-28
AU2018223435A1 (en) 2019-10-10
MX2019010042A (es) 2020-01-13
DK3587420T3 (da) 2021-06-07
AU2018223435B2 (en) 2020-12-24
KR20190120300A (ko) 2019-10-23
IL268827A (en) 2019-11-03
EP3587420B1 (en) 2021-03-31
SI3587420T1 (sl) 2021-09-30
CA3054324C (en) 2020-12-01
ZA201906135B (en) 2021-04-28
US20200247819A1 (en) 2020-08-06
ES2874656T3 (es) 2021-11-05
US11053260B2 (en) 2021-07-06
JP6764039B2 (ja) 2020-09-30
PH12019501955A1 (en) 2020-07-06
WO2018153285A1 (zh) 2018-08-30
PL3587420T3 (pl) 2021-10-11
BR112019017603A2 (pt) 2020-03-24
EP3587420A4 (en) 2020-02-19
MY175445A (en) 2020-06-29

Similar Documents

Publication Publication Date Title
CN109071544A (zh) 三并环类化合物及其应用
CN109071538A (zh) 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
KR102615733B1 (ko) 항암제로서의 치환 2-h-피라졸 유도체
JP2020189865A (ja) Btk阻害剤としての4−イミダゾピリダジン−1−イル−ベンズアミドおよび4−イミダゾトリアジン−1−イル−ベンズアミド
CN113248449B (zh) 一种含甲脒的芳基螺环类化合物及其制备方法与应用
CN110546149B (zh) 作为pcsk9抑制剂的哌啶类化合物
CA3078312A1 (en) Chemical compounds
CN102471314B (zh) 适合于特别是睡眠障碍和药物成瘾的治疗的螺氨基化合物
CN108349977A (zh) Jak抑制剂
CN105814055A (zh) 作为tnf活性调节剂的稠合咪唑和吡唑衍生物
CN110198943A (zh) 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
CN106459009A (zh) 丙肝病毒抑制剂及其制药用途
CN102089307A (zh) 作为激酶抑制剂的吡咯并吡啶
CN101479255A (zh) 用于治疗增殖性病症的c-MET蛋白激酶抑制剂
JP7168149B2 (ja) Fgfr阻害剤としてのピラジン-2(1h)-オン系化合物
CN112566907A (zh) 作为ret抑制剂的吡唑衍生物
CN101602741A (zh) 作为γ-分泌酶抑制剂的取代的N-芳基磺酰基杂环胺
CN108069959A (zh) 一种含氮杂环类化合物、其制备方法、药物组合物及应用
CN110325517A (zh) 螺环类化合物及其应用
CN109790145A (zh) 二氢嘧啶类化合物及其制备方法和用途
CN110382463A (zh) Hdac6选择性抑制剂及其制备方法和应用
CN112789087A (zh) Pad酶的苯并咪唑抑制剂
CN110483514A (zh) 一种氰基取代的环肼衍生物及其应用
CN110023286A (zh) 作为ccr2/ccr5受体拮抗剂的联苯化合物
CN110418790B (zh) 作为p53-MDM2抑制剂的咪唑并吡咯酮化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 355399 Fuyuan Industrial Zone, Dongyuan Township, Zherong County, Ningde City, Fujian Province

Applicant after: FUJIAN COSUNTER PHARMACEUTICAL Co.,Ltd.

Address before: 350003 Block B, Building 10, Software Park B, 89 Software Avenue, Gulou District, Fuzhou City, Fujian Province

Applicant before: FUJIAN COSUNTER PHARMACEUTICAL Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190617

Address after: 350003 Block B, Building 10, Software Park B, 89 Software Avenue, Gulou District, Fuzhou City, Fujian Province

Applicant after: FUJIAN COSUNTER PHARMACEUTICAL Co.,Ltd.

Address before: 350003 Block B, Building 10, Software Park B, 89 Software Avenue, Gulou District, Fuzhou City, Fujian Province

Applicant before: FUJIAN COSUNTER PHARMACEUTICAL Co.,Ltd.

Applicant before: MEDSHINE DISCOVERY Inc.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002127

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220214

Address after: 355300 building 1-7, Fuyuan Industrial Park, Zherong County, Ningde City, Fujian Province

Patentee after: Fujian Guangsheng Zhonglin Biotechnology Co.,Ltd.

Address before: 355399 Fuyuan Industrial Zone, Dongyuan Township, Zherong County, Ningde City, Fujian Province

Patentee before: FUJIAN COSUNTER PHARMACEUTICAL Co.,Ltd.